AMRN Quote, Financials, Valuation and Earnings

Akari Therapeutics PLC has a net margin of -59.42% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -7.2% beat Akari Therapeutics PLC's return on equity of --.

Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 109.6%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 8147.42%. Given that Akari Therapeutics PLC has higher upside potential than Amarin Corp PLC, analysts believe Akari Therapeutics PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.791, suggesting its less volatile than the S&P 500 by 20.903%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Amarin Corp PLC's net income of -$25.1M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -59.42% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -7.2% beat DBV Technologies SA's return on equity of --.

Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 109.6%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that DBV Technologies SA has higher upside potential than Amarin Corp PLC, analysts believe DBV Technologies SA is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42.3M, which are larger than DBV Technologies SA quarterly revenues of --. Amarin Corp PLC's net income of -$25.1M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -59.42% compared to Amarin Corp PLC's net margin of --. Amarin Corp PLC's return on equity of -7.2% beat Genfit SA's return on equity of --.

Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 109.6%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 170.55%. Given that Genfit SA has higher upside potential than Amarin Corp PLC, analysts believe Genfit SA is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.458%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Genfit SA quarterly revenues of --. Amarin Corp PLC's net income of -$25.1M is higher than Genfit SA's net income of --. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Genfit SA's PE ratio is 33.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus 2.75x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -59.42% compared to Amarin Corp PLC's net margin of -31.41%. Amarin Corp PLC's return on equity of -7.2% beat Trinity Biotech PLC's return on equity of --.

Amarin Corp PLC has a consensus price target of --, signalling upside risk potential of 109.6%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1775%. Given that Trinity Biotech PLC has higher upside potential than Amarin Corp PLC, analysts believe Trinity Biotech PLC is more attractive than Amarin Corp PLC.

Amarin Corp PLC has a beta of 1.831, which suggesting that the stock is 83.086% more volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.133%.

Amarin Corp PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amarin Corp PLC pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Amarin Corp PLC quarterly revenues are $42.3M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Amarin Corp PLC's net income of -$25.1M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Amarin Corp PLC's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amarin Corp PLC is 0.81x versus 0.15x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.